Day: November 27, 2023

New Peer-Reviewed Study Shows That Olleyes VisuALL VRP is Comparable to HVF and Offers Valuable Supplement to Standard Automated Perimetry for Pediatric Patients

Study completed at Duke University shows that the VisuALL is suitable substitute for HVF when testing pediatric patients.SUMMIT, NJ /...

Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)

Phase 1 ex-US trial achieved primary objective of predictable pharmacokinetic profiling with favorable safety and tolerabilityCompany expects to engage FDA...

ADvantage Therapeutics Has Commenced Enrollment for Its Phase 2b Clinical Trial of AD04™ for Treatment of Alzheimer’s Disease

MIAMI, Nov. 27, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), a pioneer in developing therapies for...

error: Content is protected !!